XOMA deal closed, adding scale to a growing royalty book
- Ligand is a biotech royalty aggregator, meaning it gets paid when partners sell drugs tied to its rights.
- Q2 2026 royalty revenue rose 32% year over year to $48 million, driven by Filspari and Ohtuvayre.
- The recently closed XOMA acquisition added over 120 assets, including exposure to Roche's Vabysmo.
- A new $700 million convertible note offering provides substantial capital for future royalty purchases.
- The bear case centers on generic risks for older assets like Kyprolis and regulatory delays for pipeline programs.
Scale secured, execution next
Ligand offers a cleaner way to own biotech upside. It does not need to build large sales teams for every drug. Instead, it owns royalty rights and gets paid when partner drugs sell.
The thesis strengthened in 2026 after the company closed its XOMA acquisition, absorbing over 120 assets and more than $110 million in tax attributes. Core royalty growth remains strong, with a 32% increase in Q2 driven by assets like Filspari and Ohtuvayre. A $700 million convertible note also added massive dry powder for more deals.
However, new scale brings new pressures. Older cash cows like Kyprolis are already declining in sales, and generic competition for Evomela is a reality. Meanwhile, regulatory delays, like Mirum's pushed timeline for PSC, show that royalty streams are still vulnerable to typical biotech hurdles.
Finn sees a mixed picture. Business performance and growth are solid, but valuation scores suggest the market is pricing in significant execution risk. Ligand must now prove it can integrate XOMA cheaply and deploy its new capital wisely.
Paid when partners win
Ligand makes money in three main ways: royalties on partnered drugs, sales of Captisol material, and contract revenue from fees or milestones. Royalties are the core growth engine, reaching $48 million in Q2 2026.
This model can be highly profitable. Ligand collects from many drug programs while keeping its own cost base small. The XOMA acquisition highlights this efficiency, with management expecting to run those new assets on less than $5 million in operating expenses.
The major tradeoff is control. Ligand does not run the drug trials or sales launches. If a partner struggles or a drug faces generic competition, Ligand's cash flow falls even if its own team performed perfectly.
Capital allocation is the other critical lever. Ligand relies on buying or funding royalty rights at attractive prices. With $700 million newly raised, the discipline to avoid overpaying will define the company's next phase.
The royalty basket
XOMA royalty portfolio
The closed acquisition added over 120 assets, most notably royalties on Roche's Vabysmo and potential milestone payments.
Filspari
Travere's Filspari is approved for IgAN and FSGS, driving 96% year-over-year U.S. net sales growth in Q2 2026.
Kyprolis and Evomela
These older royalties face generic pressure. Kyprolis net sales declined 17% in Q2 2026, and Evomela generics are now a factor.
Captisol
Captisol is a drug solubility technology. Revenue is uneven because customer orders shift between quarters, with 2026 sales expected to be heavily backloaded.
Ohtuvayre
A newer asset driving strong growth, with net sales increasing 98% year over year in Q2 2026. Ligand receives a 3% royalty.
Volixibat
A pipeline asset with Mirum for PSC. Regulatory changes pushed the expected NDA submission to the first half of 2027.
Mix dominated by royalties
The mix uses Q1 2026 revenue categories, as full segment breakdowns for Q2 2026 were not immediately available. Royalties remain the primary revenue driver.
What could break the story
Generic cliffs in older royalties
High impact · High oddsRoyalty assets have finite lives. Kyprolis sales are already falling 17% year over year, and Evomela faces generic competition. New assets must scale fast enough to replace this lost cash.
Partner execution risk
High impact · Medium oddsLigand depends on partners to win approvals and sell drugs. Delayed timelines, like Mirum's PSC submission pushing to 2027, defer expected returns.
Capital deployment discipline
High impact · Medium oddsLigand raised $700 million via convertible notes. While this provides dry powder, having excess cash can tempt management to overpay for assets in the sub-$100 million deal market.
XOMA integration costs
Medium impact · Low oddsManagement promised to run the newly acquired XOMA portfolio with less than $5 million in operating expenses. Failing to meet this target would drag down margins.
Viking TR-Beta dispute
Medium impact · Medium oddsViking continues to dispute Ligand's termination of the TR-Beta program license. A negative outcome could result in legal costs or lost economics for a high-interest asset.
In one breath
What does Ligand Pharmaceuticals actually do?
Ligand owns rights to payments from drugs that other companies develop and sell. It also licenses technologies like Captisol, which helps make certain drugs easier to formulate.
Why is the XOMA acquisition important for Ligand?
XOMA added over 120 assets to Ligand's portfolio, instantly diversifying revenue. The deal also brought valuable tax attributes while testing management's integration skills.
Is Ligand a normal biotech company?
No. A normal biotech spends heavily to discover and sell its own drugs. Ligand operates more like a royalty owner, meaning partner success dictates its cash flow.
